NeuroBo Pharma: DMC Recommends Continuation Of Phase 2/3 Trial Of ANA001 Without Modification

NeuroBo Pharmaceuticals, Inc. (NRBO) announced Data Monitoring Committee's recommendation to continue enrollment of the phase 2/3 clinical trial, without modification, for lead drug candidate, ANA001, as a potential treatment for COVID-19. The company plans to complete the phase 2 portion of the trial in the fourth quarter of the current year and to achieve a number of value-creating milestones with this program in the coming months, including initiation of the phase 3 of trial.

The phase 2 part of the trial is anticipated to enroll 60 patients and the primary objective is to assess safety and tolerability. The phase 3 is expected to enroll several hundred patients, with the primary endpoints being median time to hospital discharge, safety and tolerability.

Shares of NeuroBo Pharmaceuticals were up 19% in pre-market trade on Wednesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals. United Airlines operated Thursday the first ever passenger flight using 100% Sustainable Aviation Fuel or SAF as part of its efforts to combat climate change. The airline flew the green flight from Chicago's O'Hare International Airport or ORD to Washington, D.C.'s Reagan National Airport or DCA with more than 100 passengers.
Follow RTT